Redeye provides its review of Acarix following the release of the Q2 report, which came in roughly in line with our estimates. We are also encouraged by the progress in the UAE, where the company has now gained regulatory approval for the CADScor System. On the back of the report, we have pushed some of our revenue ramp-up estimates further into the future, while highlighting that our outlook on the company remains intact. We reiterate our fundamental valuation (base case) and present our new Fair Value of SEK0.4, with the stock screening as "Fairly Priced".
LÄS MER
